首页> 外文期刊>Journal of managed care pharmacy : >Prevalence of drug-related problems and cost-savings opportunities in medicaid high utilizers identified by a pharmacist-run drug regimen review center.
【24h】

Prevalence of drug-related problems and cost-savings opportunities in medicaid high utilizers identified by a pharmacist-run drug regimen review center.

机译:药房杂草药物方案审查中心确定的药品提高利用者中有关毒品相关问题和成本节约机会的患病率。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Despite numerous reports of state Medicaid drug utilization review (DUR) programs, little data are available about the prevalence of drugrelated problems (DRPs) in Medicaid patients. A university-based, pharmacist-run DUR program for high utilizers was created as an alternative to imposition of a statutory limit of 7 medications per month in the Utah Medicaid program in 2002. The DUR program was designed to suggest ways that high-utilizing patients could decrease their total number of medications to 7 or fewer prior to imposition of the 7-medication limit at some time in the future. OBJECTIVE: To describe the experience in 1 Medicaid DUR program and to report the prevalence of DRPs and cost-saving opportunities (CSOs) among a population of Medicaid recipients who were high utilizers of prescription drugs. METHODS: DRPs were identified by 5 clinical pharmacists employed by the Drug Regimen Review Center (DRRC) in Salt Lake City. The purpose of the center was to provide drug therapy review services for a select number of Utah Medicaid recipients (200-300 per month) who exceeded a 7-medication limit during the calendar years 2003 and 2004. RESULTS: Out of 391,890 eligible Medicaid recipients, 242,411 (62%) received at least 1 medication, and 16,958 (4.3%) exceeded the 7-medication limit during the review period. Of those exceeding the limit, the DRRC reviewed a total of 3,706 (21.9%) patients, representing the highest utilizers by volume of medication. The prevalence of DRPs considered clinically important in the review cohort was 79.7% of patients, including therapeutic duplications in 54.6% of patients, dose form optimization in 29.7%, and inappropriate uncoordinated care in 25.3%. The average pharmacy cost per month for patients with at least 1 DRP was 1,081 dollars; by contrast, the average pharmacy cost per month for all other patients receiving at least 1 prescription was 91 dollars. CONCLUSIONS: Approximately 4% of Medicaid recipients exceeded the 7-medication monthly limit. Among the 22%highest utilizers in this group, 48% of nursing home residents and 87% of ambulatory recipients had at least 1 DRP, or an overall rate of 80% of high-use Medicaid recipients or as much as 3.2% of the Medicaid population.
机译:背景:尽管有许多国家医疗补助药物利用审查(DUR)计划的报告,但在医疗补助患者中有关脱褶问题(DRPS)的普遍存在的普遍存在的情况下提供了很少的数据。基于大学的药剂师运行的高利用者的DUR计划是替代于2002年在犹他州医疗补助计划中每月每月施加7种药物的替代方案。DUR计划旨在建议高利用患者的方式在未来的某个时间施加7药物限制之前,可以将其总数减少到7或更少的药物。目的:描述1家医疗补助DUR计划的经验,并在医疗补助人口中报告了DRPS和节省成本的机会(CSOS)的普遍存在的处方药。方法:由盐湖城药物审查中心(DRRC)雇用的5名临床药剂师鉴定DRPS。该中心的目的是为在2003年和2004年历年期间超过7药物限制的犹他州医疗补助受助者(200-300每月200-300)提供药物治疗审查服务。结果:符合391,890符合条件的医疗补助保险人,242,411(62%)在审查期间收到至少1种药物,16,958(4.3%)超过7药物限制。其中超过极限,DRRC共审查了3,706名(21.9%)患者,代表了由药物量的最高利用者。在审查队列中临床重要的DRPS的患病率为79.7%的患者,包括54.6%的患者治疗重复,剂量形式的优化29.7%,不适当的未下属护理25.3%。至少1个DRP的患者的每月平均药房成本为1,081美元;相比之下,所有其他患者接受至少1处方的所有其他患者的平均药房费用为91美元。结论:约4%的医疗补助受者超过7药物月度限额。在本集团的22%最高利用者中,48%的护理家庭居民和87%的动态受者至少有1个DRP,或80%的高价医疗补助受助者的总体税率或高额的医疗补助3.2%人口。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号